Home
    • Plans Blog Contact
    Indaptus Therapeutics Inc logo

    Indaptus Therapeutics Inc

    INDP
    Last price US$2.62
    Market cap US$292.2m
    12M price change -73.51%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Indaptus Therapeutics Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Indaptus Therapeutics Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 15, 2026

    Quarterly result summary

    Net loss was -$2.5M.

    Net loss -$2.5M reported

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    The Company expects that any future development or collaborative opportunities under evaluation will be assessed based on scientific validation, clinical and regulatory considerations, resource availability and overall development planning.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 15, 2026 SEC filing 8-K May 15, 2026 SEC filing 10-K Mar 17, 2026 SEC filing 10-Q Nov 12, 2025 Earnings release Earnings release Nov 12, 2025 SEC filing 8-K Nov 12, 2025 SEC filing 10-Q Aug 13, 2025 Earnings release Earnings release Aug 13, 2025 SEC filing 8-K Aug 13, 2025 SEC filing 10-Q May 14, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    No qualified company news in the last 14 days

    No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

    Earnings Per Share

    Score 1.00/5
    Indaptus Therapeutics Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 0.68/5
    Indaptus Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Indaptus The... INDP US$292.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Indaptus Therapeutics Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Indaptus The... INDP US$292.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 3.47/5
    Indaptus Therapeutics Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Indaptus The... INDP US$292.2m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Indaptus Therapeutics Inc logo

    Indaptus Therapeutics Inc

    US$2.62

    US$292.2m

    3.56%

    -73.51%